Eintrag weiter verarbeiten
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant
Gespeichert in:
| Zeitschriftentitel: | American Journal of Hematology |
|---|---|
| Personen und Körperschaften: | , , , , |
| In: | American Journal of Hematology, 82, 2007, 10, S. 932-933 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Abidi, Muneer H. Tove, Isaacson Ibrahim, Rami B. Maria, Dan Peres, Edward Abidi, Muneer H. Tove, Isaacson Ibrahim, Rami B. Maria, Dan Peres, Edward |
|---|---|
| author |
Abidi, Muneer H. Tove, Isaacson Ibrahim, Rami B. Maria, Dan Peres, Edward |
| spellingShingle |
Abidi, Muneer H. Tove, Isaacson Ibrahim, Rami B. Maria, Dan Peres, Edward American Journal of Hematology Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant Hematology |
| author_sort |
abidi, muneer h. |
| spelling |
Abidi, Muneer H. Tove, Isaacson Ibrahim, Rami B. Maria, Dan Peres, Edward 0361-8609 1096-8652 Wiley Hematology http://dx.doi.org/10.1002/ajh.20913 <jats:title>Abstract</jats:title><jats:p>Histiocytic sarcoma (HS) is a rare neoplasm of uncertain etiology. Most recently, the diagnostic criteria for this entity have been revised with inclusion of diagnostic modalities such as immunohistochemical and cytogentic techniques. HS tends to have an aggressive clinical course and presents with systemic symptoms of fever, weight loss, adenopathy, hepatosplenomegly, rash, and pancytopenia. Thalidomide is a promising agent that may exert a therapeutic benefit in HS. We report a case of a 48‐year‐old female with HS who presented with fever, weight loss, fatigue, generalized anasarca, and pancytopenia. She underwent multi‐agent chemotherapy followed by matched unrelated hematopoietic stem cell transplant. Her disease recurred and thalidomide therapy was started, with her overall disease burden significantly reduced as measured radiographically. Am. J. Hematol. 82:932–933, 2007. © 2007 Wiley‐Liss, Inc.</jats:p> Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant American Journal of Hematology |
| doi_str_mv |
10.1002/ajh.20913 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hamguMjA5MTM |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hamguMjA5MTM |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 |
| imprint |
Wiley, 2007 |
| imprint_str_mv |
Wiley, 2007 |
| issn |
0361-8609 1096-8652 |
| issn_str_mv |
0361-8609 1096-8652 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
abidi2007thalidomideforthetreatmentofhistiocyticsarcomaafterhematopoieticstemcelltransplant |
| publishDateSort |
2007 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
American Journal of Hematology |
| source_id |
49 |
| title |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_unstemmed |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_full |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_fullStr |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_full_unstemmed |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_short |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_sort |
thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| topic |
Hematology |
| url |
http://dx.doi.org/10.1002/ajh.20913 |
| publishDate |
2007 |
| physical |
932-933 |
| description |
<jats:title>Abstract</jats:title><jats:p>Histiocytic sarcoma (HS) is a rare neoplasm of uncertain etiology. Most recently, the diagnostic criteria for this entity have been revised with inclusion of diagnostic modalities such as immunohistochemical and cytogentic techniques. HS tends to have an aggressive clinical course and presents with systemic symptoms of fever, weight loss, adenopathy, hepatosplenomegly, rash, and pancytopenia. Thalidomide is a promising agent that may exert a therapeutic benefit in HS. We report a case of a 48‐year‐old female with HS who presented with fever, weight loss, fatigue, generalized anasarca, and pancytopenia. She underwent multi‐agent chemotherapy followed by matched unrelated hematopoietic stem cell transplant. Her disease recurred and thalidomide therapy was started, with her overall disease burden significantly reduced as measured radiographically. Am. J. Hematol. 82:932–933, 2007. © 2007 Wiley‐Liss, Inc.</jats:p> |
| container_issue |
10 |
| container_start_page |
932 |
| container_title |
American Journal of Hematology |
| container_volume |
82 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792340855403577350 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T16:10:35.565Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Thalidomide+for+the+treatment+of+histiocytic+sarcoma+after+hematopoietic+stem+cell+transplant&rft.date=2007-10-01&genre=article&issn=1096-8652&volume=82&issue=10&spage=932&epage=933&pages=932-933&jtitle=American+Journal+of+Hematology&atitle=Thalidomide+for+the+treatment+of+histiocytic+sarcoma+after+hematopoietic+stem+cell+transplant&aulast=Peres&aufirst=Edward&rft_id=info%3Adoi%2F10.1002%2Fajh.20913&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792340855403577350 |
| author | Abidi, Muneer H., Tove, Isaacson, Ibrahim, Rami B., Maria, Dan, Peres, Edward |
| author_facet | Abidi, Muneer H., Tove, Isaacson, Ibrahim, Rami B., Maria, Dan, Peres, Edward, Abidi, Muneer H., Tove, Isaacson, Ibrahim, Rami B., Maria, Dan, Peres, Edward |
| author_sort | abidi, muneer h. |
| container_issue | 10 |
| container_start_page | 932 |
| container_title | American Journal of Hematology |
| container_volume | 82 |
| description | <jats:title>Abstract</jats:title><jats:p>Histiocytic sarcoma (HS) is a rare neoplasm of uncertain etiology. Most recently, the diagnostic criteria for this entity have been revised with inclusion of diagnostic modalities such as immunohistochemical and cytogentic techniques. HS tends to have an aggressive clinical course and presents with systemic symptoms of fever, weight loss, adenopathy, hepatosplenomegly, rash, and pancytopenia. Thalidomide is a promising agent that may exert a therapeutic benefit in HS. We report a case of a 48‐year‐old female with HS who presented with fever, weight loss, fatigue, generalized anasarca, and pancytopenia. She underwent multi‐agent chemotherapy followed by matched unrelated hematopoietic stem cell transplant. Her disease recurred and thalidomide therapy was started, with her overall disease burden significantly reduced as measured radiographically. Am. J. Hematol. 82:932–933, 2007. © 2007 Wiley‐Liss, Inc.</jats:p> |
| doi_str_mv | 10.1002/ajh.20913 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9hamguMjA5MTM |
| imprint | Wiley, 2007 |
| imprint_str_mv | Wiley, 2007 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1 |
| issn | 0361-8609, 1096-8652 |
| issn_str_mv | 0361-8609, 1096-8652 |
| language | English |
| last_indexed | 2024-03-01T16:10:35.565Z |
| match_str | abidi2007thalidomideforthetreatmentofhistiocyticsarcomaafterhematopoieticstemcelltransplant |
| mega_collection | Wiley (CrossRef) |
| physical | 932-933 |
| publishDate | 2007 |
| publishDateSort | 2007 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | American Journal of Hematology |
| source_id | 49 |
| spelling | Abidi, Muneer H. Tove, Isaacson Ibrahim, Rami B. Maria, Dan Peres, Edward 0361-8609 1096-8652 Wiley Hematology http://dx.doi.org/10.1002/ajh.20913 <jats:title>Abstract</jats:title><jats:p>Histiocytic sarcoma (HS) is a rare neoplasm of uncertain etiology. Most recently, the diagnostic criteria for this entity have been revised with inclusion of diagnostic modalities such as immunohistochemical and cytogentic techniques. HS tends to have an aggressive clinical course and presents with systemic symptoms of fever, weight loss, adenopathy, hepatosplenomegly, rash, and pancytopenia. Thalidomide is a promising agent that may exert a therapeutic benefit in HS. We report a case of a 48‐year‐old female with HS who presented with fever, weight loss, fatigue, generalized anasarca, and pancytopenia. She underwent multi‐agent chemotherapy followed by matched unrelated hematopoietic stem cell transplant. Her disease recurred and thalidomide therapy was started, with her overall disease burden significantly reduced as measured radiographically. Am. J. Hematol. 82:932–933, 2007. © 2007 Wiley‐Liss, Inc.</jats:p> Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant American Journal of Hematology |
| spellingShingle | Abidi, Muneer H., Tove, Isaacson, Ibrahim, Rami B., Maria, Dan, Peres, Edward, American Journal of Hematology, Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant, Hematology |
| title | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_full | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_fullStr | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_full_unstemmed | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_short | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_sort | thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| title_unstemmed | Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant |
| topic | Hematology |
| url | http://dx.doi.org/10.1002/ajh.20913 |